Business Information
The group's principal activity is the research and development of pharmaceutical products for a range of medical disorders. Its product portfolio comprises drugs targeting a variety of diseases and disorders such as migraines, arterial occlusion, Parkinson's diseases, cancer, obesity, inflammatory and depression. Some of the group's products includes frovatriptan, v10153, v2006, v140, 5-ht2c agonist, meis, a2a antagonists, hsp90 and cb1 antagonists
|
|
Name |
Title
|
Email
|
| George Kennedy | Dep. Chmn. | N/A | | Peter Fellner | Executive Chmn. | N/A | | Anthony Weir | Dir., CFO | N/A | | Allan Baxter | Non Exec. Dir. | N/A | | Carol Ferguson | Non Exec. Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2005 | 24,317 | (130,672) | | 2004 | 29,275 | (56,503) | | 2003 | 8,909 | (52,076)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
